(Q35666918)

9 August 2017

1 reference

title

Programmes and principles in treatment of multidrug-resistant tuberculosis (English)

1 reference

9 August 2017

0 references

multiple drug resistance

1 reference

13

Mary C Smith Fawzi

1 reference

9 August 2017

7

Jennifer J Furin

1 reference

9 August 2017

8

Mercedes C Becerra

1 reference

9 August 2017

Joia S Mukherjee

1

1 reference

9 August 2017

Michael L Rich

2

1 reference

9 August 2017

Adrienne R Socci

3

1 reference

9 August 2017

J Keith Joseph

4

1 reference

9 August 2017

Felix Alcántara Virú

5

1 reference

9 August 2017

Sonya S Shin

6

1 reference

9 August 2017

Donna J Barry

9

1 reference

9 August 2017

Jim Yong Kim

10

1 reference

9 August 2017

Jaime Bayona

11

1 reference

9 August 2017

Paul Farmer

12

1 reference

9 August 2017

Kwonjune J Seung

14

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

9 August 2017

1 reference

9 August 2017

volume

363

1 reference

9 August 2017

issue

9407

1 reference

9 August 2017

page(s)

474-481

1 reference

Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Tuberculosis in New York City--turning the tide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

PUBLIC HEALTH: Responding to Market Failures in Tuberculosis Control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Increasing transparency in partnerships for health--introducing the Green Light Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Transmission of multidrug-resistant Mycobacterium tuberculosis during a long airplane flight

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Multidrug-resistant tuberculosis in patients without HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Treatment experience of multidrug-resistant tuberculosis in Florida, 1994-1997.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

The treatment of multidrug-resistant tuberculosis in Turkey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Multidrug-resistant tuberculosis: long term follow-up of 40 non-HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Improved outcomes for patients with multidrug-resistant tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Outcome of MDR-TB patients, 1983-1993. Prolonged survival with appropriate therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Multicenter quality control study of amikacin assay for monitoring once-daily dosing regimens. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Activity of amikacin against Mycobacteria in vitro and in murine tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Pharmacology of the antimycobacterial drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

A controlled comparison of thiacetazone (thioacetazone) plus isoniazid with PAS plus isoniazid in Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Cytogenetic effects of chemotherapy with three combinations of anti-tubercular drugs involving isoniazid, thiacetazone, para-aminosalicylic acid and streptomycin on human lymphocytes: chromosome aberrations, sister chromatid exchanges and mitotic in

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

VIRULENCE IN THE GUINEA-PIG AND SENSITIVITY TO PAS AND THIACETAZONE OF TUBERCLE BACILLI FROM SOUTH INDIAN PATIENTS WITH PULMONARY TUBERCULOSIS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Antituberculosis activities of clofazimine and its new analogs B4154 and B4157

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Activity of amoxicillin/clavulanate in patients with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Antituberculosis activity of clarithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Clarithromycin is inactive against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Thiacetazone: in vitro activity against mycobacterium avium and m. tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Therapy of multidrug-resistant tuberculosis: lessons from studies with mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Metronidazole therapy in mice infected with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Therapeutic drug monitoring in the treatment of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915496-2

7 January 2021

10.1016/S0140-6736(04)15496-2

Identifiers

DOI

1 reference

9 August 2017

1 reference